Literature DB >> 30222440

Choosing Appropriate Estimands in Clinical Trials.

Ann-Kristin Leuchs1, Jörg Zinserling1, Andreas Brandt1, Dorothee Wirtz1, Norbert Benda1.   

Abstract

Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial's planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.

Keywords:  clinical trials; effectiveness; efficacy; estimands; missing data; nonadherence

Year:  2015        PMID: 30222440     DOI: 10.1177/2168479014567317

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  8 in total

Review 1.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

2.  Estimands and missing data in clinical trials of chronic pain treatments: advances in design and analysis.

Authors:  Xueya Cai; Jennifer S Gewandter; Hua He; Dennis C Turk; Robert H Dworkin; Michael P McDermott
Journal:  Pain       Date:  2020-10       Impact factor: 7.926

3.  Bootstrapping complex time-to-event data without individual patient data, with a view toward time-dependent exposures.

Authors:  Tobias Bluhmki; Hein Putter; Arthur Allignol; Jan Beyersmann
Journal:  Stat Med       Date:  2019-06-04       Impact factor: 2.373

4.  Estimands in epigenome-wide association studies.

Authors:  Jochen Kruppa; Miriam Sieg; Gesa Richter; Anne Pohrt
Journal:  Clin Epigenetics       Date:  2021-04-29       Impact factor: 6.551

Review 5.  Estimands: bringing clarity and focus to research questions in clinical trials.

Authors:  Timothy Peter Clark; Brennan C Kahan; Alan Phillips; Ian White; James R Carpenter
Journal:  BMJ Open       Date:  2022-01-03       Impact factor: 2.692

6.  Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.

Authors:  Ian R White; Babak Choodari-Oskooei; Matthew R Sydes; Brennan C Kahan; Leanne McCabe; Anna Turkova; Hanif Esmail; Diana M Gibb; Deborah Ford
Journal:  Clin Trials       Date:  2022-05-17       Impact factor: 2.599

7.  "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?

Authors:  H-G Eichler; B Bloechl-Daum; P Bauer; F Bretz; J Brown; L V Hampson; P Honig; M Krams; H Leufkens; R Lim; M M Lumpkin; M J Murphy; F Pignatti; M Posch; S Schneeweiss; M Trusheim; F Koenig
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

8.  On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Authors:  Steffen Unkel; Marjan Amiri; Norbert Benda; Jan Beyersmann; Dietrich Knoerzer; Katrin Kupas; Frank Langer; Friedhelm Leverkus; Anja Loos; Claudia Ose; Tanja Proctor; Claudia Schmoor; Carsten Schwenke; Guido Skipka; Kristina Unnebrink; Florian Voss; Tim Friede
Journal:  Pharm Stat       Date:  2018-11-20       Impact factor: 1.894

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.